WallStreetZenWallStreetZen

NASDAQ: SMTI
Sanara Medtech Inc Stock

$37.00-0.30 (-0.8%)
Updated Mar 28, 2024
SMTI Price
$37.00
Fair Value Price
N/A
Market Cap
$319.04M
52 Week Low
$26.06
52 Week High
$50.18
P/E
-71.15x
P/B
7.12x
P/S
5.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$64.99M
Earnings
-$4.30M
Gross Margin
87.9%
Operating Margin
-5.89%
Profit Margin
-6.6%
Debt to Equity
0.65
Operating Cash Flow
-$3M
Beta
0.68
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SMTI Overview

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Zen Score

–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SMTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SMTI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SMTI is poor value based on its book value relative to its share price (7.12x), compared to the US Medical Instruments & Supplies industry average (3.75x)
P/B vs Industry Valuation
SMTI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SMTI due diligence checks available for Premium users.

Be the first to know about important SMTI news, forecast changes, insider trades & much more!

SMTI News

Valuation

SMTI fair value

Fair Value of SMTI stock based on Discounted Cash Flow (DCF)
Price
$37.00
Fair Value
-$34.22
Undervalued by
208.12%
SMTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SMTI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-71.15x
Industry
53.11x
Market
44.51x

SMTI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.12x
Industry
3.75x
SMTI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SMTI's financial health

Profit margin

Revenue
$17.7M
Net Income
-$237.2k
Profit Margin
-1.3%
SMTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SMTI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$73.9M
Liabilities
$29.3M
Debt to equity
0.65
SMTI's short-term assets ($19.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SMTI's short-term assets ($19.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SMTI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SMTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$848.5k
Investing
-$54.3k
Financing
-$185.9k
SMTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SMTI vs Medical Stocks

TickerMarket Cap1d %P/EP/B
SMTI$319.04M-0.80%-71.15x7.12x
UTMD$255.21M+1.33%15.53x1.99x
NYXH$386.81M+1.73%-8.03x3.63x
ANGO$233.95M+2.98%-16.77x0.58x
AKYA$230.47M-0.85%-3.28x4.29x

Sanara Medtech Stock FAQ

What is Sanara Medtech's quote symbol?

(NASDAQ: SMTI) Sanara Medtech trades on the NASDAQ under the ticker symbol SMTI. Sanara Medtech stock quotes can also be displayed as NASDAQ: SMTI.

If you're new to stock investing, here's how to buy Sanara Medtech stock.

What is the 52 week high and low for Sanara Medtech (NASDAQ: SMTI)?

(NASDAQ: SMTI) Sanara Medtech's 52-week high was $50.18, and its 52-week low was $26.06. It is currently -26.27% from its 52-week high and 41.98% from its 52-week low.

How much is Sanara Medtech stock worth today?

(NASDAQ: SMTI) Sanara Medtech currently has 8,622,805 outstanding shares. With Sanara Medtech stock trading at $37.00 per share, the total value of Sanara Medtech stock (market capitalization) is $319.04M.

Sanara Medtech stock was originally listed at a price of $3,300.00 in Dec 31, 1997. If you had invested in Sanara Medtech stock at $3,300.00, your return over the last 26 years would have been -98.88%, for an annualized return of -15.86% (not including any dividends or dividend reinvestments).

How much is Sanara Medtech's stock price per share?

(NASDAQ: SMTI) Sanara Medtech stock price per share is $37.00 today (as of Mar 28, 2024).

What is Sanara Medtech's Market Cap?

(NASDAQ: SMTI) Sanara Medtech's market cap is $319.04M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sanara Medtech's market cap is calculated by multiplying SMTI's current stock price of $37.00 by SMTI's total outstanding shares of 8,622,805.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.